INSTITUTO DE INVESTIGACIONES EN CIENCIAS DE LA SALUD
Unidad Ejecutora - UE
CLOMIPRAMINE AND BENZNIDAZOLE ASSOCIATION FOR THE TREATMENT OF ACUTE EXPERIMENTAL Trypanosoma cruzi INFECTION
MARIANA STRAUSS; M. SILVINA LO PRESTI; PAULA CAROLINA BAZÁN; ALEJANDRA BAEZ; ROMINA FAURO; BLANCA ESTEVES; OLGA SÁNCHEZ NEGRETTE; DAVID CREMONEZZI; PATRICIA A. PAGLINI-OLIVA ; H. WALTER RIVAROLA
ELSEVIER IRELAND LTD
Lugar: Amsterdam ; Año: 2013 vol. 62 p. 293 - 293
Alternative strategies are being designed to identify candidates among drugs already available on the market that could be used in combination to improve the efﬁcacy of Chagas disease treatment. This work evaluates the effect of the association of clomipramine (CLO) with benznidazole (BZN) for the treatment of experimen- tal Chagas disease in the acute stage, in Swiss albino mice infected with Trypanosoma cruzi Tulahuen strain. Infected mice were treated with CLO 5 mg/kg/day and BZN 50 and 100 mg/kg/day, each separately or togeth- er. Efﬁcacy of the treatment was evaluated through parasitemia, survival, electrocardiography, histopatho- logical studies, serological and PCR assays at 90 days post-infection (dpi). All treatments signiﬁcantly (P b 0.05) reduced mortality and decreased parasitemia. Histopathological analysis of liver and kidneys of mice treated with CLO and the drug combination showed less injury than mice treated only with BZN. The lower dose of BZN (50 mg/kg/day) combined with CLO showed the same efﬁcacy as the habitual dose of BZN (100 mg/kg/day) combined with CLO. The therapeutic results from the combination of BZN with CLO presented lesser side effects than the treatment with BZN.